



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/36, 37/26	A1	(11) International Publication Number: WO 93/23071 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/SE93/00425 (22) International Filing Date: 14 May 1993 (14.05.93) (30) Priority data: 9201573-4 19 May 1992 (19.05.92) SE (71) Applicant (for all designated States except US): KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : DUNGER, David, B. [GB/GB]; 9 Chapel Street, St Clemens, Oxford, Oxfordshire (GB). SAVAGE, Martin, O. [GB/GB]; 55 Doneraile Street, London SW6 6EN (GB). SÖNKSEN, Peter, H. [GB/GB]; 2 Friston Street, London SW6 3AT (GB).		(74) Agents: TANNERFELDT, Agneta et al.; Kabi Pharmacia AB, S-112 87 Stockholm (SE). (81) Designated States: AU, CA, FI, JP, NO, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: USE OF IGF-1 (57) Abstract The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

USE OF IGF-I

The present invention relates to the use of insulin-like growth factor (IGF-I) for the manufacture of a medicament for treatment of Type 1 diabetes mellitus (IDDM), the medicament comprising a subcutaneous dose to achieve an IGF-I serum level characteristic for healthy individuals, especially in children, adolescents and young adults. Evidence for the efficacy of such treatment is presented in adolescents with insulin dependent Type 1 diabetes mellitus.

Background

Human IGF-I (hIGF-I) is a peptide present in plasma and other body fluids. It has been purified from human plasma and the complete amino acid sequence is known. The primary sequence comprises 70 amino acids, including 3 disulphide bonds. Moreover, purified IGF-I:s from plasma of other species show extensive sequence homologies to hIGF-I.

hIGF-I can stimulate growth of a wide range of cell types. It has both systemic and local effects and is present in the circulation mainly associated with different binding proteins, six of which are sequenced (IGFBP1-6). The binding proteins appear to modulate the biological functions and availability of IGF-I variably. IGF-I analogues with changed biological activities seemingly related to changes of affinities to the binding proteins have been produced.

IGF-I appears to act mainly through the IGF-type 1 receptor exposed on the outer surface of many different cell types. However, the relative specificity of action may vary at the cell level, for example, due to varying influence of binding proteins. The structures of the IGF-I and insulin receptors are closely homologous, but binding of IGF-I and insulin show only limited cross-reactivity.

Because of the scarcity of purified plasma hIGF-I, there was a great need to develop methodology for a commercial scale production. Nowadays such large scale production of hIGF-I can readily be achieved by using recombinant DNA techniques.

IGF-I is primarily involved in mediating the somatogenic effects of growth hormone (GH). As a result of studies with preparations of recombinant DNA derived hIGF-I, it has been demonstrated that it promotes skeletal growth and skeletal muscle protein synthesis. Moreover, hIGF-I is also effective for the treatment or prevention of catabolic states (WO 92/03154).

In WO 91/12018 (Ballard *et al.*) the therapeutic use of IGF-I, or a peptide analogue thereof, for gastrointestinal disease or the treatment of the shortened gut after surgery was disclosed.

It has also been found that IGF-I improves the regeneration of transected peripheral nerves (EP 308 386) and it has previously been demonstrated *in vitro* that IGF-I promotes actin synthesis in myocytes in culture (Florini, J R, Muscle and Nerve, 10 (1987) 577-598), and contractility of neonatal rat cardiocytes (Vetter, U *et al.*, Basic Res. Cardiol. 83 (1988) 647-654).

Large doses of hIGF-I do lower blood glucose in non-diabetic animals and humans (Zapf J *et al.* J Clin-Invest, Jun Vol:77(6) (1986) 1768-75 and Guler H-P *et al.* N Engl. J. Med, 317 (1987) 137-140). In these studies the hypoglycaemic effect of hIGF-I was around 1.5-7% of that of insulin. Recent studies in the depancreatized dog demonstrated that as an agent for lowering blood glucose hIGF-I was 8-11% as potent as insulin (Giacca A *et al.*, Diabetes, 39 (1990) 340-347). However, these studies also demonstrated that the metabolic effects of IGF-I may be quite distinct from those of insulin. The glucose lowering effects of IGF-I were largely mediated by increased glucose uptake, while glucose production rates remained unchanged. One explanation for this observation might be the relative paucity of IGF-I receptors in adult liver (Caro J F *et al.*, J. Clin. Invest, 81 (1988) 976-981). It is likely that the effects of IGF-I are largely mediated through muscle. Similar distinctions in the distribution of receptors may

explain the less potent antilipolytic effects of IGF-I as compared to insulin *in vitro* (Bolinder *et al.*, J. Clin. Endocrinol. Metab, 65, (1987) 732-737) and *in vivo* (Zapf J *et al.* 1986, Guler H-P *et al.* 1987, Giacca A *et al.* 1990). IGF-I decreases proteolysis and reduces amino acid levels in non-diabetic rats (Jacob R *et al.*, J Clin. Invest, 83, (1989) 1717-1723). Furthermore, in the studies of Giacca A *et al.*, 1990, a rise in lactate was observed which did not occur with an equipotent dose (for glucose lowering) of insulin.

IGF-I circulates predominantly as a large 150K complex (IGFBP3) comprising a 53K GH-dependent acid stable IGF binding component and an acid labile subunit. The smaller 28-35K binding protein (IGFBP1) is not growth hormone dependent and shows a marked circadian variation which is inversely related to insulin (Brismar K *et al.*, J Endocrinol Invest, 11(1988) 599-602, Cotterill AM *et al.*, J Clin Endocrinol Metabol, 67 (1988) 882-887, Holly JMP *et al.*, Clin Endocrinol, 29 (1988) 667-675). Measured circulating IGF-I level appears to be mainly determined by the available capacity of IGFBP3 whereas IGFBP1 seems to be primarily involved in other functions such as transport of IGF-I from the circulating pool or modulation of biological actions in the tissues (Holly JMP *et al.*, J Endocrinol, 121 (1989) 383-387, and Diabetic Medicine, 7 (1990) 618-23).

Insulin deficiency also results in high levels of IGFBP1 which is believed to inhibit the biological activity of IGF-I (Taylor AM *et al.*, Clin Endocrinol, 32 (1990) 229-239).

Age-related changes in plasma IGF-I in healthy subjects have been investigated (Smith C P *et al.*, J Clin. Endocrin. Metab, Vol 68, No 5, (1989) 932-937). It was found that basal plasma IGF-I concentrations rose significantly throughout puberty and declined to prepubertal levels by the third decade of life. The concentration was about 1 U/ml before and after puberty and about 2 U/ml during puberty.

It was not previously known how the different IGFBP profile in diabetics would affect the bioavailability or bioactivity of endogenous or exogenously administered IGF-I.

Increased overnight GH serum concentrations have been compared between diabetic and normal adolescents (Edge J A et al, J. Clin. Endocrinol. metab, Vol. 71, No 5, (1990) 1356-1362) and it was found that GH baseline and peak levels were higher in the diabetic than in the control subjects.

In EP 331 630 (Ciba-Geigy) a method is disclosed for treatment and preventing secondary effects of hyperinsulinaemia in Type 1 diabetes mellitus by administering hIGF-I. In the description the dose of hIGF-I used is around 500µg/kg/day. hIGF-I was given to two healthy (non-diabetic) subjects receiving 20µg/kg/h during six days by continuous subcutaneous infusion. The amount given per day is 10 times the endogenous production of hIGF-I (approximately 50µg/kg/day). With such a high dose of hIGF-I an insulin-like effect is to be expected.

The authors interpreted the results obtained as indicating that these high doses of IGF-I resulted in a decrease of insulin degradation and a prolongation of its half-life. They concluded that hIGF-I makes the organism more sensitive to insulin and therefore a lower dose of insulin can be used. Thus, by administration of hIGF-I, less exogenous insulin would be needed and hyperinsulinaemia due to large doses of insulin can be avoided or minimised. However, the route of administration and particularly the high doses used in the example have a very limited clinical applicability. The dose 480 µg/kg/day given as a continuous infusion results in very high (supraphysiological) serum levels of IGF-I. Such concentrations cannot be regarded as safe and clinically applicable.

In contrast to the findings in EP 331 630, we have found that a physiological restoration of circulating IGF-I levels gives reduced GH levels through a feed back mechanism. This normalisation of GH and IGF-I levels lead to an increased sensitivity for insulin and to a

reduction in the dawn phenomenon (the rapid increase in the morning blood glucose levels seen in type 1 diabetics) and thereby providing better long term control.

The possible clinical value of a therapy with IGF-I to restore physiological IGF-I levels and thereby alter the growth hormone/IGF-I axis, have not earlier been considered.

The GH/IGF-I axis in diabetes

Insulin dependent diabetes causes profound derangements in the GH/IGF-I axis. In poorly controlled Type 1 diabetics, GH levels are invariably raised. The elevated GH levels are characterised by a greater pulse amplitude and higher baseline concentration of GH as compared to the levels of normal subjects. Recent studies on the signal mode of GH indicate that it is the pulse amplitude rather than the increased baseline which lead to profound changes in insulin resistance in diabetic subjects (Pal *et al.*, Diabetologia, in press). The high GH levels lead to insulin resistance and aggravate the metabolic abnormalities of diabetes. GH excess has also been implicated in the aetiology of the dawn phenomenon and may accelerate the development of microangiopathy including proliferative retinopathy. Finally, an excessive rise in beta hydroxy buturate (BOH) caused by raised GH has been observed, particularly during puberty, and is compounded by the effects of insulin waning overnight; this leads to the risk of rapid decompensation with diabetic ketoacidosis in adolescents with diabetes.

Despite the elevated GH levels, IGF-I levels tend to be low in diabetes and this is related to decreased GH receptor function resulting from low levels of insulin (Holly JMP *et al.*, Clin. Endocrinol, 29 (1988) 667-675). The lower IGF-I levels in the

presence of elevated GH levels has been implicated in the slow growth and loss of adult height in children with diabetes (Salardi S *et al.* Arch. Dis. Child, 62, (1987) 57-62) .

The mechanism underlying the increased GH levels has been the subject of some controversy. In the diabetic individual hyperglycaemia does not inhibit GH secretion as it does in healthy individuals and it has been proposed that this reflects an altered hypothalamic function. This altered hypothalamic function is characterised by reduced somatostatin levels and resistance to the effects of somatostatin. Suppression of plasma GH by somatostatin analogues and pirenzepine has led to reported improvement in metabolic control. However, this approach has proved inappropriate during childhood and adolescence when growth is rapid as it would inevitably lead to growth failure.

It has been argued that the excessive GH release may relate to low IGF-I levels. However, Shaper *et al.* (Acta Endocrinol, 122 (1990), suppl, 32-39) reasoned against this hypothesis as they could not observe any negative correlation between serum IGF-I levels and GH responses to GH releasing hormone in such patients.

In light of this controversy it is remarkable that our preliminary studies indicated that a single subcutaneous physiological replacement dose of IGF-I in adolescents with diabetes led not only to a reduction in GH levels but also to a statistically significant reduction of insulin requirement on that single occasion. The relatively long-lasting effect from a single injection was also surprising and opens the possibility of single dose subcutaneous administration, especially in treatment of children, adolescents and young adults with diabetes.

The following figures are presented:

- Fig 1: Mean blood glucose and mean IGF-I levels at 18.00 to 09.00 hours
- Fig 2: Mean growth hormone levels at 18.00 to 16.00 hours
- Fig 3: Mean growth hormone levels for Group A and Group B and per individual at 20.00 to 08.00 hours
- Fig 4: Mean serum insulin levels at 02.00 to 08.00 hours
- Fig 5: Mean percentage insulin requirement during stable blood glucose levels at 02.00 to 08.00 hours
- Fig 6: IGF-I levels at -1, 0 and 4 week, respectively, for each patient, Example 2.

The invention

Our study is the first study in diabetics which shows that IGF-I given in physiological doses has a significant feed-back effect on GH levels and GH secretion. Physiological replacement of IGF-I led to a significant reduction of insulin requirement which was mediated by the reduction in GH levels rather than any direct effects of free IGF-I as reported in previous studies.

The invention relates to the use of IGF-I for the manufacture of a medicament for treatment of Type 1 diabetes mellitus, (IDDM, Insulin Dependant Diabetes Mellitus) the medicament comprising a subcutaneous dose to achieve an IGF-I serum level characteristic for healthy individuals i.e. not greater than needed to achieve the physiological replacement of IGF-I in serum. This treatment would be especially valuable for the treatment of children, adolescents or young adults with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.

The medicament can also be used for an improved and stabilised glycaemic control, for reduced brittleness, for reduced risk for acute decompensation and for reduced incidence of diabetic ketoacidosis in Type 1 diabetes mellitus.

The invention also relates to the use of IGF-I for the manufacture of medicament comprising a subcutaneous dose to achieve an IGF-I

serum level characteristic for healthy individuals for reducing insulin requirements for children, adolescents and young adults with Type 1 diabetes mellitus.

The medicament could comprise IGF-I alone or be in combination with an insulin preparation.

The medicament is preferably adapted for a single injection which could be given once or twice a day, one, two or three times a week or from one up to seven days per month. The medicament can also be given as a depot or slow release preparation and should thereby be adopted for that. The invention also relates to a method for the treatment of Type 1 diabetes mellitus, the medicament comprising a subcutaneous dose to achieve an IGF-I serum level characteristic for healthy individuals.

The physiological serum IGF-I level is about 1U/ml for a healthy adult and about twice as high during puberty.

1 U/ml of IGF-I corresponds to about 200 ng/ml of IGF-I.

The invention is novel and inventive because it was never previously realised that the restoration of normal IGF-I bioactivity would lead to such dramatic reductions in GH secretion and profound effects on insulin requirement. The implications for this invention are profound in that IGF-I treatment might lead to prolonged improvements in glycaemic control and a reduction in the risk of diabetic complications.

This discovery was surprising in that the previous studies indicated that, in normal subjects, only pharmacological doses of IGF-I would lead to any GH suppression. Further, it was argued that IGF-I would only be of value in diabetics if used in the pharmacological doses necessary to obtain direct insulin-like effects. The profound effects of physiological replacement therapy in Type 1 diabetes mellitus has never previously been proposed.

The clinical improvements would include:

- Improved glycaemic control and consequences thereof (e.g. normalisation of serum lipids, reduced risk for late vascular complications)
- Stabilised glycaemic control, e.g. reduced brittleness (fewer unpredictable and incapacitating episodes of hyper- and hypoglycaemia) and reduced risk for acute decompensation
- Reduced incidence of diabetic ketoacidosis.
- A more normalised pubertal growth.

EXAMPLES

Assays

Whole blood glucose, measured every 15 minutes, was determined by the glucose oxidase method (YSI analyser, Clandon Scientific Ltd, Hants, UK).

Samples for GH assay, taken every 15 minutes, were kept at room temperature until the profile was complete and then they were spun, separated and the plasma frozen at -20° C until assay.

Plasma GH concentrations were measured by immunoradiometric assay (IRMA.) using the International Reference Standard 80/505. All the samples from each individual profile were analysed in the same batch. The inter-assay coefficients of variation at GH concentrations of 3.5, 15.2 and 77.4 mU/L were 9.4, 7.7 and 10.5 %, respectively, and the nitre-assay coefficients of variation at GH concentrations of 2.9, 14.3 and 69.4 mU/L were 8.0, 2.0 and 3.4 %, respectively.

For plasma free **insulin**, measured hourly, 1.0 ml of whole blood was added immediately to 0.6 ml of ice-cold 25 % polyethylene glycol (PEG 6,000) and then spun at 300 rpm for 20 minutes before separation (Collins ACG and Pickup JC, Diab Med, 2 (1985) 456-460). The plasma was stored at -20° C and assayed by a double-antibody radioimmunoassay (Guildhay Antisera Ltd) modified from

Morgan and Lazarow (Diabetes, 12 (1963) 115-126). Interassay coefficients of variation at 12.2 and 47.2 mU/L were 5.5 and 8.6 %, respectively.

A pulse detection programme, Pulsar (Merriam GR and Wachter KW, Am J Physiol, 243 (1982) E310-E318) was used to analyse 12 hour **GH profiles** between 22.00 and 08.00 hours. It detects hormone pulses as deviations from a smoothed detrended baseline using the assay standard deviation as a scale factor.

Blood glucose and insulin infusion data were normally distributed. Log-transformation normalised the plasma free insulin data and therefore parametric statistical techniques were used. Analyses of variance (Two-way ANOVA) was used to examine changes with time. Data are expressed as Mean \pm Standard Error of the Mean (SE) unless otherwise stated.

Glycosylated haemoglobin (HbA_{1c}) was measured by using the Diamat Dedicated HPLC System.

Plasma IGF-I was measured by standard RIA after acid-ethanol extraction. The maximum sensitivity of one assay is 10 μ g/l. The inter-and intra-assay variations were less than 10 % and 8 % respectively, at analyte concentration 2.3, 1.2 and 0.2 μ g/ml.

Example 1

Nine adolescents with Type 1 Insulin Dependent Diabetes (five females and four males) aged between 14 and 18 years and at late puberty stage 4 or 5 (Tanner) participated in a cross-over double-blind placebo-controlled trial of IGF-I administered subcutaneously at a dose of 40 μ g/kg body weight. The volume of IGF-I or placebo subcutaneously administered, calculated at 40 μ g/kg body weight, was in the range of 1.0 to 1.5 ml IGF-I or placebo was given at 18.00. Blood glucose was controlled at 5 mmol/L overnight by an insulin varying glucose clamp. When treated according to the Group A protocol the subjects received

placebo and when treated in Group B they received IGF-I. The duration of the study was 22 hours.

Subjects were of normal height and weight (median weight 62.5 kg, range 50.3 to 73.9 kg) with a Body Mass Index (BMI) less than 26 kg/m² and had been diagnosed as having Type 1 diabetes for at least 3 complete years. C-peptide levels ranged from less than 0.025 to 0.275 nmol/L (median 0.047 nmol/L). The subjects were in good general health with normal hepatic, renal and thyroid function and were all using a combination of short and intermediate acting insulin administered either twice or four times daily (median dose 1.0 U/kg/day, range 0.6 to 1.5 U/kg/day). Subjects were not taking any regular medication apart from one individual who inhaled beclomethasone dipropionate, 200 µg three times daily for treatment of asthma. Median glycated haemoglobin (Total HbA1) at the time of the study was 13.5 % with a range of 7.1 to 17.0 %. Details of the subjects participating in the study are summarised in Table I.

Table I

PATIENT DETAILS

NUMBER	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>
AGE (years)	14	14	17	14	18	18	17	15	15
SEX	M	F	M	F	F	F	M	F	M
PUBERTY STAGE (G / P.H.)	5/4	4/4	5/5	5/5	5/4	5/5	5/5	4/4	5/5
WT. (kg)	61.0	50.3	64.0	66.9	51.4	73.9	72.0	54.9	68.2
INSULIN DOSE (mU/kg)	1.0	1.5	0.8	1.0	1.3	0.6	1.5	0.9	1.2
HbA1 (%)	17.0	15.6	7.1	15.5	14.3	10.5	13.3	13.7	8.4

One subject (3) was excluded from most of the analysis because of asymptomatic hypoglycaemia during the study, see below. Of the remaining eight patients four had been randomised to receive IGF-I during the first study period.

Results

Blood glucose

No subject experienced hypoglycaemic symptoms during the study period overnight. However, for subject 3 the lowest blood glucose was 3.3 mmol/L during Period A and 2.5 mmol/L during Period B under placebo and IGF-I treatment, respectively. In both instances the individual concerned was subject number 3. For the purposes of this study hypoglycaemia has been defined as values below 3.5 mmol/L. By adopting a relatively high threshold we hope to have ensured that counter-regulatory responses to hypoglycaemia which could affect the study outcome have not been evoked. Data from the two study periods for subject number 3 has therefore been excluded from the overall analysis of growth hormone production and insulin requirements. The two study periods were one or two weeks apart, except in one subject where they were six weeks apart.

A stable blood glucose was reached by 02.00 hours in both groups of subjects, and remained stable throughout 08.00 hours. See Fig. 1. Mean blood glucose between 02.00 and 08.00 hours in study groups A (control) and B (IGF-I) was 5.62 ± 0.13 and 5.59 ± 0.07 mmol/L, respectively. Two-way analysis of variance between groups and within groups did not reveal any significant difference in blood glucose values.

IGF-I

Mean blood levels of IGF-I rose from 223.2 ng/ml to a peak of 413.1 ng/ml 5.5 hours after the injection of recombinant IGF-I. Levels 30 minutes post-injection were significantly higher than after placebo administration (251.8 ± 17.6 versus 202.1 ± 18.7 ng/ml, $p=0.002$) and then remained elevated throughout the study period overnight. (Overall mean values on IGF-I study night: 359.4 ± 25.9 versus placebo: 206.1 ± 22.3 ng/ml; $p<0.001$) see Fig. 1.

Growth hormone

Growth hormone production has been analysed throughout the study period (18.00 to 16.00) and also overnight between 20.00 and 08.00. Mean values obtained from 15 minute sampling have been used.

There was an overall significant reduction in growth hormone levels in the period when IGF-I was administered when compared to the period when placebo was given (16.92 ± 3.21 versus 27.77 ± 4.88 mU/L; $p = 0.011$ paired "t" test). Mean values throughout the 22 hours are shown in Fig 2.

A significant reduction was also seen overnight from 20.00 until 08.00 hours (19.38 ± 4.03 versus 33.65 ± 5.78 mU/L; $p = 0.009$; paired "t" test). See Fig 3.

The Pulsar programme demonstrated a significant reduction in growth hormone mean peak amplitude after IGF-I administration (41.1 ± 7.1 versus 75.2 ± 12.2 mU/L; $p = 0.01$) and in the mean calculated baseline growth hormone concentrations (1.4 ± 0.5 versus 8.2 ± 2.5 mU/L; $p = 0.02$).

Insulin

Insulin requirements during the 22 hours study period can be divided into the initial stage leading to the establishment of a stable blood glucose, the clamp period itself and finally the interval between breakfast and the study ending at 16.00 hours. The insulin infused between the time of IGF-I or placebo administration and the establishment of a stable insulin varying glucose clamp at 02.00 hours was not significantly different between group A (IGF-I) and group B (control); (0.57 ± 0.08 versus 0.51 ± 0.06 mU/kg/min; $p = 0.436$).

A stable blood glucose was established by 02.00 hours as described above. Analysis of the insulin infusion during the period 02.00 to 08.00 hours showed a significant reduction in the insulin requirements to maintain euglycaemia in the group receiving IGF-I when compared to the control group. (0.25 ± 0.12 versus 0.31 ± 0.07

mU/kg/min; $p = 0.03$ paired "t" test). The insulin infusion data (U/kg body weight) has also been analysed by an assessment of percentage change during the period 02.00 to 08.00 hours. By using the mean insulin requirement in Group A treatment in each individual subject as the divisor, the overall difference between Groups A and B during the clamp has been expressed as a mean percentage at each individual time point. See Fig 4.

Because the insulin requirement for Group A has been used as the divisor the overall sum of the percentage values in that group will be one hundred. Paired "t" testing of the mean percentage values for Groups A and B in each individual subject confirms the significant reduction in insulin requirement after IGF-I administration. (81.4 versus 100 %; $p = 0.002$).

Mean plasma free insulin levels were also reduced during this period after IGF-I administration. (67.88 ± 15.96 versus 31.90 ± 2.74 mU/L; $p = 0.001$) Fig. 5.

Example 2

A follow up study was undertaken in order to evaluate whether IGF-I levels were sustained over a 28 days treatment period with IGF-I, i.e. that the endogenous production of IGF-I was not suppressed.

Four male patients with type 1 insulin dependent diabetes mellitus aged between 15 and 19 years and of Tanner puberty stages 3-5 for genitalia and 2-5 for pubic hair, respectively, were treated with rhIGF-I during a 4-week period.

Visit schedule during the study was the following:

Visit - 4 weeks - - - - 1 week:	Screening visits
Visit 0 week:	First injection of IGF-I given at 18.00, thereafter overnight profile.
Visit 1 week - - - 4 weeks:	Treatment period, last IGF-I injection given at 18.00 on 4 week visit, thereafter overnight profile.
Visit 8 week:	Follow-up visit

The dose of 40µg/kg IGF-I was administered subcutaneously in the thigh once daily at 18.00 hours for 28 consecutive days.

All subjects participating in the study had a diabetes duration of at least 5 years (range 5-10 years). The subjects were in good health with normal hepatic and renal function. All patients were euthyroid at initiation of treatment and were using a combination of short and intermediate acting insulin administered four times daily.

Subjects were not taking any regular medication than insulin. Median glycated haemoglobin A (HbA₁/HbA_{1c}) at the screening visit (- 1 week) was 11.2/9.7 % with a range of 9.9/8.5 to 14.0/12.3 %. Details of the subjects participating in the study are summarised in Table 2.

No patient had any evidence of nephropathy or retinopathy at the initiation of the study.

Table 2

PATIENT DETAILS

NUMBER	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>
AGE (years)	15	15	19	16
SEX	M	M	M	M
PUBERTY STAGE	5/5	3/2	5/5	5/5
(G / P.H.)				
WT. (kg)	61.0	78.0	38.5	83.8
				28.7

Results**Metabolic control**

Measured as HbA₁C(1%), which is a marker for metabolic control. The normal range for healthy is approximately 5-6 % for HbA₁C.

The individual data for the four patients are shown in Figure 6.

Glycated haemoglobin levels, measured as HbA₁C(1%), tended to decrease during the 4 week treatment period and returned to a higher level after the IGF-I treatment (Figure 6). Although one month observation period is too short to confirm a change in metabolic control (assessed by measurement of HbA₁C), a deterioration at discontinuation of IGF-I treatment implies that metabolic control can be affected by IGF-I. The observed changes lead further support to the invention that IGF-I treatment improves glycaemic and metabolic control.

IGF-I

Table 3 shows the individual data for meanvalue over one night profile.

Table 3 IGF-I (U/ml)

PAT no	Week		
	- 1	0 *	4 **
1	1.34	2.04	2.48
2	0.90	1.51	2.02
3	1.13	1.82	2.48
4	1.37	2.07	2.16

* after first injection at 18.00 of IGF-I.

** after four weeks of daily injection of IGF-I.

During the 4 week treatment period IGF-I levels were maintained at normal physiological levels in healthy individuals of this age group.

Furthermore no suppression of endogenous IGF-I secretion was noted during the treatment period.

As a consequence, the long term normalisation of IGF-I levels would imply a normalisation of longitudinal growth in children and adolescence with IDDM.

CLAIMS

1. Use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus, the medicament comprising a subcutaneous dose to achieve an IGF-I serum level characteristic for healthy individuals.
2. Use of IGF-I for the manufacture of a medicament according to claim 1 for the treatment of children, adolescents and young adults with Type 1 diabetes mellitus.
3. Use of IGF-I for the manufacture of a medicament according to claim 2 for reducing insulin requirements for children, adolescents and young adults with Type 1 diabetes mellitus.
4. Use of IGF-I for the manufacture of a medicament according to claim 1 for an improved and stabilised glycaemic control in Type 1 diabetes mellitus.
5. Use of IGF-I for the manufacture of a medicament according to claim 4 for reduced brittleness in Type 1 diabetes mellitus.
6. Use of IGF-I for the manufacture of a medicament according to claim 4 for reduced risk for acute decompensation in Type 1 diabetes mellitus.
7. Use of IGF-I for the manufacture of a medicament according to claim 1 for reduced incidence of diabetic ketoacidosis for Type 1 diabetes mellitus.
8. Use of IGF-I for the manufacture of a medicament according to claim 2 for the improvement of a pubertal growth in children and adolescents with Type 1 diabetes mellitus.

9. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament comprises an insulin preparation.
10. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament is adapted for a single injection.
11. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament is adapted for a single injection once or twice a day.
12. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament is adapted for a single injection from one up to three times a week
13. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament is adapted for a single injection from one up to seven days a month.
14. Use of IGF-I for the manufacture of a medicament according to claim 1 in which the medicament is adapted for depot or slow release preparation.
15. Method for the treatment of Type 1 diabetes mellitus by subcutaneous administration of IGF-I in a dose to achieve an IGF-I serum level characteristic in healthy individuals.

1/6




Figure 1

SUBSTITUTE SHEET

2/6

MEAN GROWTH HORMONE

18-00 to 16-00


---○--- group B
(IGF-1)---●--- group A
(placebo)

Figure 2

SUBSTITUTE SHEET

3/6

MEAN GROWTH HORMONE 20-00 to 08-00
Group A (Placebo) and Group B (IGF-1)




Figure 3

SUBSTITUTE SHEET

4/6




Figure 4
SUBSTITUTE SHEET

5/6




Figure 5
SUBSTITUTE SHEET

6/6




Figure 6

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 93/00425

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 37/36, A61K 37/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, EMBASE, MEDLINE, WPI, CHEMICAL ABSTRACTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A1, 0331630 (CIBA-GEIGY AG), 6 Sept 1989 (06.09.89)	1-14
X	WO, A1, 9103253 (GREATER GLASGOW HEALTH BOARD), 21 March 1991 (21.03.91)	1-8, 10-14
X	DIABETOLOGIA, Volume 34, 1991, E.J. Schoenle et al, "Recombinant human insulin-like growth factor I(rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance" page 675 - page 679	1-8, 10-14

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 Sept. 1993

Date of mailing of the international search report

11-09-1993

Name and mailing address of the ISA
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Elisabeth Carlborg
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 93/00425

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TRENDS IN ENDOCRINOLOGY AND METABOLISM, Volume, May 1990, (6), E. Rudolf Froesch et al, "Therapeutic Potential of Insulinlike Growth Factor I" page 254 - page 260 --	1-8,10-14
X	DIABETES, Volume 40, April 1991, Luciano Rossetti et al, "Metabolic Effects of IGF-I in Diabetic Rats" page 444 - page 448 --	1-14
X	Chemical Abstracts, Volume 114, No 114, 15 April 1991 (15.04.91), (Columbus, Ohio, USA), Jacob, Ralph J et al, "Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats", page 109, THE ABSTRACT No 136379k, Am. J. Physiol. 1991, 260 (2Pt.1), E262-E268 -----	1-8,10-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 93/00425

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15
because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/07/93

International application No.

PCT/SE 93/00425

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0331630	06/09/89	SE-T3- 0331630 AU-A- 2899989 DE-U- 6890520 JP-A- 1233227 US-A- 4988675	10/08/89 15/04/93 19/09/89 29/01/91
WO-A1- 9103253	21/03/91	AU-A- 6358090 EP-A- 0490955	08/04/91 24/06/92